Vulnerable GOP senators up for reelection next year are giving the cold shoulder to a bipartisan bill aimed at lowering drug prices.

Senate Finance Committee Chairman Chuck Grassley Charles (Chuck) Ernest GrassleyGOP lawmakers distance themselves from Trump comments on transfer of power The Hill's 12:30 Report: Ginsburg lies in repose Top GOP senators say Hunter Biden's work 'cast a shadow' over Obama Ukraine policy MORE (R-Iowa) is pushing for passage of his measure with Sen. Ron Wyden Ronald (Ron) Lee WydenHillicon Valley: Subpoenas for Facebook, Google and Twitter on the cards | Wray rebuffs mail-in voting conspiracies | Reps. raise mass surveillance concerns On The Money: Anxious Democrats push for vote on COVID-19 aid | Pelosi, Mnuchin ready to restart talks | Weekly jobless claims increase | Senate treads close to shutdown deadline Democratic senators ask inspector general to investigate IRS use of location tracking service MORE (D-Ore.) to lower drug prices, something seen as a rare area for possible bipartisan agreement this year.

ADVERTISEMENT

Grassley is explicitly and publicly making the case to Senate Majority Leader Mitch McConnell Addison (Mitch) Mitchell McConnellDemocratic senator to party: 'A little message discipline wouldn't kill us' House to vote on resolution affirming peaceful transition of power Republican lawyers brush off Trump's election comments MORE (R-Ky.) that his bill would help vulnerable Republicans. However, many of those incumbents have declined to support the Grassley-Wyden bill.

GOP Sens. Thom Tillis Thomas (Thom) Roland TillisOvernight Energy: Trump officials finalize plan to open up protected areas of Tongass to logging | Feds say offshore testing for oil can proceed despite drilling moratorium | Dems question EPA's postponement of inequality training On The Trail: Making sense of this week's polling tsunami Feds say offshore testing for oil can proceed despite drilling moratorium MORE (N.C.), Martha McSally Martha Elizabeth McSallyOn The Trail: Making sense of this week's polling tsunami The Hill's Campaign Report: Presidential polls tighten weeks out from Election Day Mark Kelly: Arizona Senate race winner should be sworn in 'promptly' MORE (Ariz.), Cory Gardner Cory Scott GardnerBreaking the Chinese space addiction Trump dumbfounds GOP with latest unforced error Billionaire who donated to Trump in 2016 donates to Biden MORE (Colo.) and Joni Ernst Joni Kay ErnstOn The Trail: Making sense of this week's polling tsunami Tillis appears to reinforce question about COVID-19 death toll The power of incumbency: How Trump is using the Oval Office to win reelection MORE (Iowa), who all face potentially tough races next year, have either expressed concerns about the legislation or declined to back it. Sen. Susan Collins Susan Margaret CollinsDemocratic senator to party: 'A little message discipline wouldn't kill us' Poll: 57 percent of Americans think next president, Senate should fill Ginsburg vacancy On The Trail: Making sense of this week's polling tsunami MORE (Maine) is the lone vulnerable Republican to endorse the measure.

Senators who haven't supported the bill are highlighting the bind they face. On the one hand, the bill has the support of President Trump Donald John TrumpFederal prosecutor speaks out, says Barr 'has brought shame' on Justice Dept. Former Pence aide: White House staffers discussed Trump refusing to leave office Progressive group buys domain name of Trump's No. 1 Supreme Court pick MORE, and lowering drug prices is a popular issue with voters. But on the other hand, supporting the bill breaks with GOP orthodoxy and invites a backlash from both conservatives and the pharmaceutical industry.

The most controversial provision for Republicans requires drug companies to pay money back to Medicare if their prices rise faster than inflation, something some Republicans view as too close to a “price control.”

Tillis told The Hill that he has “concerns” with the bill, saying that he wants to focus on middlemen known as pharmacy benefit managers and other parts of the supply chain, not just pharmaceutical companies themselves to lower drug prices.

“I think we need to make progress on [the bill],” Tillis said, while adding he has not made a final decision on how he would vote if the bill came to the floor.

McSally has also expressed concerns, declining to say if she would support the bill in an interview with The Arizona Republic in August.

"There are a lot of really good things in that legislation and we're making sure there's not any unintended consequences,” she said. “But we appreciate the intent. We definitely support the intent."

A McSally aide said Friday that the senator “has been in close discussions” with Grassley but did not give a firm position on the measure either way.

Gardner’s office did not respond to a request for comment on whether he supports the bill.

Ernst, Grassley’s fellow Iowan, has also so far declined to endorse the bill.

“Senator Grassley and Senator Ernst share the same goal of lowering the cost of prescription drugs for their fellow Iowans, and on this particular bill, Senator Ernst generally supports the intent of the package and is still reviewing the specifics of the proposal,” said Ernst spokeswoman Kelsi Daniell.

The wavering from GOP senators comes despite support from Trump, who frequently rails against high drug prices.

“I like Sen. Grassley’s drug pricing bill very much,” Trump tweeted last month.

Because of my Administration, drug prices are down for the first time in almost 50 years — but the American people need Congress to help. I like Sen. Grassley’s drug pricing bill very much, and it’s great to see Speaker Pelosi’s bill today. Let’s get it done in a bipartisan way! — Donald J. Trump (@realDonaldTrump) September 19, 2019

Lowering drug prices is also a major issue for voters. A Kaiser Family Foundation poll in September found that 70 percent of the public said lowering drug prices should be a “top priority.”

But conservative groups have attacked the bill for its limits on price increases in Medicare, and FreedomWorks called the idea “price controls” in July.

“We cannot afford to put our nation on the slippery slope towards socialized medicine,” the group’s president, Adam Brandon, said at the time.

The pharmaceutical industry — a powerful force in Washington and a major source of campaign contributions — is also staunchly opposed to the bill.

Some vulnerable Republican senators are pointing to smaller, less controversial bills to show their commitment to lowering drug prices.

Ernst and McSally, for example, point to their support for the Creates Act, a smaller bipartisan measure aimed at lowering drug prices by cracking down on delay tactics that drug companies use to fend off competition from cheaper generic drugs.

The pharmaceutical industry also supports that measure, helping make it less controversial than the Grassley-Wyden bill.

Grassley last month publicly called on McConnell to support his bill, arguing that it would help Republicans keep control of the Senate in next year’s elections.

He's pitched his bill to Republicans as the “moderate” alternative to Speaker Nancy Pelosi Nancy PelosiDemocratic senator to party: 'A little message discipline wouldn't kill us' Overnight Health Care: New wave of COVID-19 cases builds in US | Florida to lift all coronavirus restrictions on restaurants, bars | Trump stirs questions with 0 drug coupon plan Overnight Defense: Appeals court revives House lawsuit against military funding for border wall | Dems push for limits on transferring military gear to police | Lawmakers ask for IG probe into Pentagon's use of COVID-19 funds MORE’s (D-Calif.) drug pricing measure in the House, which is far more sweeping but has at least some chance of receiving Trump's support given his focus on drug costs.

"There's a great deal of disgust with the rapidly increasing price of drugs, and every Republican up for election's going to have to have a place to land," Grassley told reporters in September.

"And this is the place to land, because they're surely not going to land with what Pelosi's [doing]," he continued. "If McConnell wants to keep the Republican majority, then this drug pricing bill is part of that plan."

ADVERTISEMENT

Grassley spokesman Michael Zona said Friday that support is growing and more Republican supporters will be announced “in the coming days.”

Asked about the path forward for Grassley’s bill and whether it would get a vote, McConnell’s office referred back to the majority leader’s comments to Politico last month, when he said the path forward is still “under discussion” and the Senate is still “looking at doing something on drug pricing.”

However, given the bill's ability to divide McConnell's caucus, he could be hesitant to give it a vote.

Many lobbyists expect that Grassley’s bill will not come up for a vote as a standalone measure and that its only chance is to have sections included in a larger package, such as a government funding deal. However, that could be a more likely scenario for smaller measures such as the Creates Act.

With the election ahead, both sides are already throwing jabs over the issue.

“Voters are worried about prescription drugs getting more expensive, but many Republican incumbents on the ballot haven't taken meaningful steps to bring down prices and are now dodging questions about legislation,” said Democratic Senatorial Campaign Committee spokesman Stewart Boss.

Jesse Hunt, a spokesman for the National Republican Senatorial Committee, countered that Republicans “are firmly committed to addressing the rising cost of prescription drugs through a variety of different measures.”

“These attacks from Democrats are nothing more than an effort to distract voters from their party’s embrace of plans that would eliminate employer-based health care coverage,” he added.